As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

Cerebral amyloid angiopathy (CAA) has never been more relevant ... given that any potential window for treatment is likely to be at earlier stages of the disease, this is likely to significantly limit ...

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

which is developing ALN-APP in collaboration with Regeneron for both Alzheimer’s and related condition cerebral amyloid angiopathy (CAA), which can cause haemorrhaging in the brain. Eisai and ...

A protein from Helicobacter pylori inhibits amyloid formation in both microbes and humans, offering new leads for ...

Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to ...

Most migraine episodes last 4 to 72 hours without treatment. Some rare complications of migraine can cause symptoms that last longer. The diagnosis of migraine is determined based on clinical ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, ...

The drug is already approved in the EU for transthyretin amyloidosis with polyneuropathy but now covers patients with cardiomyopathy.